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METHODS: A literature search and a systematic review of the high-dose-rate (HDR) brachyther-
apy (monotherapy) prostate literature were performed on PubMed using ‘‘high-dose-rate, brachy-
therapy, prostate, monotherapy’’ as search terms. More than 80 articles and abstracts published
between 1990 and 2013 were identified. Data tables were generated and summary descriptions
created. Commentary and opinion was formulated through discussion and consensus based on
the critical review of the literature and the author’s combined personal experience and knowledge.
RESULTS: Thirteen articles reported clinical outcome and toxicity with followup ranging from
1.5 to 8.0 years. Results were available for all risk groups. A variety of dose and fractionation
schedules were described. Prostate-specific antigen progressionefree survival ranged from 79%
to 100% and local control from 97% to 100%. The toxicity rates were low. Genitourinary toxicity,
mainly frequency/urgency, was 0e16% (Grade 3). Gastrointestinal toxicity was 0e2% (Grade 3).
Erectile function preservation was 67e89%. The radiobiological, clinical, and technical features of
HDR brachytherapy were reviewed and discussed.
CONCLUSIONS: Consistently high local tumor control and low complications rates are reported
with HDR monotherapy. It provides reproducible high-quality dosimetry, it has an advantage from a
radiobiology perspective, and it has a good radiation safety profile. HDR brachytherapy is a safe
and effective local treatment modality for prostate cancer.  2014 American Brachytherapy Soci-
ety. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: Prostate; Prostate cancer; High-dose-rate brachytherapy; Radiation therapy; MonotherapyIntroduction
A literature search and systematic review of the high-
dose-rate (HDR) brachytherapy (monotherapy) prostate
literature was performed on PubMed using ‘‘high-dose-rate,
brachytherapy, prostate, monotherapy’’ as search terms.
More than 80 articles and abstracts published between
1990 and 2013 were identified. Data tables were generated
and summary descriptions created. Historical information
was derived from the literature and the author’s combined
personal experiences and knowledge. Commentary and
opinion was formulated through discussion and consensus.
HDR prostate brachytherapy began in 1986 at Kiel
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.1016/j.brachy.2014.03.002independently at the Seattle Prostate Institute in 1989 and
in 1991 at the California Endocurietherapy Cancer Center
(CET) in Oakland, California, and William Beaumont Hos-
pital (WBH) in Royal Oak, Michigan (1e6). HDR was
initially used only as a boost in conjunction with external
beam radiation therapy (EBRT) because of concerns about
the effect of large doses per fraction on normal tissues.
Dose escalation studies by Martinez et al., however, estab-
lished the safety and efficacy range for HDR in the context
of combined EBRT and HDR (7e9). During the 1990s, ul-
trasound image guidance and computer treatment planning
technology evolved, clinical experience accumulated, and
outcomes of HDR prostate brachytherapy began to be re-
ported. The clinical rationale for HDR monotherapy for
prostate cancer was derived from organ-specific treatments
such as radical prostatectomy and permanent seed mono-
therapy. Recognition of the technical capabilities of HDR
to reliably treat the prostate (and seminal vesicles) with a
margin of surrounding tissue and to simultaneously control
the dose to adjacent normal tissues led to the developmentOpen access under CC BY-NC-ND license.
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initiated in the mid-1990s at WBH and CET for low- and
intermediate-risk groups, and in Osaka, Japan for all risk
groups (9e11).
Why HDR?
HDR brachytherapy and improvements in EBRT
evolved simultaneously. Conformal EBRT and intensity
modulated radiation therapy are two technologies, which
allow physicians to deliver higher total doses and achieve
better tumor control rates. However, three major drawbacks
of conformal EBRT or intensity modulated radiation
therapy are day-to-day variations in internal anatomy
secondary to organ motion (interfraction motion), organ
deformation and other variations in internal anatomy during
radiation therapy delivery (intrafraction motion), and daily
setup inaccuracies (setup errors). To overcome these limita-
tions, HDR brachytherapy was identified as a potentially
advantageous vehicle for dose-escalation.
HDR technology combines a number of favorable quali-
ties of brachytherapy with the sophisticated treatment plan-
ning developed for EBRT. HDR brachytherapy procedures
are performed under general or spinal anesthesia, are usually
done through a perineal template guide, and use ultrasound
guidance similar to low-dose-rate (LDR) permanent seed
implants. Organ motion and setup inaccuracies are not an
issue with HDR either because they do not occur, or because
they can be corrected with interactive online dosimetry dur-
ing the procedure, or modified during simulation and treat-
ment planning before dose delivery. There is no need to
add treatment volume (margins) beyond the intended target
to account for patient motion or variations in beam delivery.
Common problems associated with permanent seeds im-
plants such as discrepancy between planned and actual
seeds distribution, inability to correct seeds position or to
optimize the dose delivered once the seeds are in place,
and operator dependency are relatively low in HDR brachy-
therapy, particularly with the introduction of intraoperative
online HDR treatment planning and delivery (12, 13).
Important features of HDR brachytherapy
1. HDR catheters are relatively easy to visualize with
transrectal ultrasound (TRUS), and they can be
safely implanted outside the prostate capsule and
into the seminal vesicles without the risk of seed
migration.
2. HDR avoids uncertainties in dosimetry (target dose)
associated with prostate volume changes that occur
with permanent seed brachytherapy. Immediate
swelling and subsequent gland shrinkage due to
fibrosis are irrelevant.
3. Real-time dose modulation HDR planning software
offers immediate feedback for the physician and phys-
icist to achieve optimal implant catheter distributions.4. HDR planning provides multiparametric dose opti-
mization through modulation of catheter geometry,
dwell position, and dwell time. HDR dosimetry is
‘‘high density’’ because there are approximately
twice as many HDR dwell positions as seeds in the
typical permanent seed prostate (LDR) implant.
5. The versatility of intratarget dose modulation
inherent to brachytherapy can be controlled and
directed with HDR to deliver high doses to gross dis-
ease (concomitant boost), or it can be used to selec-
tively reduce the dose to parts of the prostate or
organs-at-risk (OARs) as in partial prostate irradia-
tion (focal therapy). This process is sometimes
described as dose sculpting or dose painting.
6. HDR dosimetry is prospective (known and approved
before treatment delivery), and it consistently pro-
vides good target coverage and normal organ sparing
(14).
7. The low alpha/beta ratio (estimated 1.2e4) means
that the large fraction sizes used in HDR have a rela-
tively high biological effectiveness for prostate can-
cer (15e17).
8. HDR is applicable to a wide range of clinical cir-
cumstances in prostate cancer.
9. A single radioactive source may deliver treatment to
large numbers of patients and it can be used for
many disease sites. The modality can be deployed
in a cost-effective manner.
10. HDR treatment courses are of short duration, and re-
covery from acute side effects is comparatively brief.
11. HDR radiation safety is good because patients are
not radioactive after the procedure. As such, patients
do not need to follow special precautions such as
limiting distance or duration of contact with other
adults, children, or pregnant women. Likewise, there
are no issues in handling radioactive sources by
pharmacy or medical personnel.
12. Because androgen deprivation therapy (ADT) has
not been shown to enhance disease control with
prostate HDR monotherapy, and as ADT is usually
not required for downsizing of prostate volume with
HDR brachytherapy, it can usually be omitted, at
least in low- and intermediate-risk group cases.Patient and case selection
Patients whose disease is confined to the prostate or im-
mediate surrounding tissue are ideal candidates for locally
directed treatments such as prostatectomy, EBRT, or
brachytherapy alone. National Comprehensive Cancer
Network defined low- and intermediate-risk cases are more
likely to have disease confined to the prostate region and,
therefore, are logically the best candidates for local treat-
ment (National Comprehensive Cancer Network guidelines
version 1.2014 at www.nccn.org/professionals/physician_
gls/pdg/prostate.pdf).
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monotherapy in high-risk group patients based on the idea
that it provides a treatment margin greater than radical
prostatectomy and that there is no convincing evidence
showing an improvement in outcome by treating the pelvic
lymph nodes. The use of HDR monotherapy in high-risk
group disease is being tested because it can reliably
distribute dose around the prostate and into the seminal ves-
icles. It creates a dose margin without the risk of seed
migration, and the dose to the bladder and rectum remain
significantly lower than when treating with EBRT.
HDR brachytherapy is technically feasible after tran-
surethral resection of the prostate (TURP) because it uses
a scaffolding of catheters rather than prostate tissue to hold
the radiation source and the dose to the prostatic urethra
can be controlled to limit toxicity (18). Careful urethral
dosimetry (maximum dose not exceeding 110% of the pre-
scribed dose) and waiting at least 3 months after TURP to
allow wound healing are recommended. In the authors’
experience, by following these measures, HDR brachyther-
apy can be safely administered after TURP.
HDR brachytherapy enables treatment of prostates
across a wide range of gland sizes for a variety of reasons
including, among other things, the use of a catheter matrix,
dwell time modification, and the relatively high energy of
the source. It has been shown that prostate glands larger
than 50 cm3 can be treated with HDR without the need
of hormonal downsizing (19, 20). The authors have suc-
cessfully treated prostate glands larger than 100 cm3.
Although prostate size does not always correlate with
symptom scores, highly symptomatic patients can be ex-
pected to have more urinary outflow issues after brachy-
therapy than patients who are not symptomatic. However,
HDR appears to be less likely to cause prolonged exacerba-
tion of urination symptoms than LDR or EBRT because
even patients with International Prostate Symptom Score
(IPSS) of 20 or higher tend to have a relatively rapid return
to pretreatment baseline urinary function status (20).
Prior pelvic radiation, inflammatory bowel disease, and
prior pelvic surgery are not contraindications to prostate
HDR brachytherapy, but the dosimetry must include care-
fully defined normal tissue constraints and there must be
full disclosure to the patient of the additional potential
risks. Normal tissue sparing is substantially better with
HDR than with EBRT and the dose distribution more accu-
rate and predictable than with LDR (21e23). Finally, HDR
is one of the salvage treatment options for locally recurrent
prostate cancer (24e28).HDR planning and dosimetry: CT or MRI scan vs.
TRUS-based
There are currently two common ways to perform
dosimetry and treatment planning for prostate HDR brachy-
therapy, based on the image acquisition modality and itstiming relative to the insertion of the brachytherapy cathe-
ters: CT-based and real-time TRUS based. Each method has
advantages and disadvantages; choosing one or the other is
a matter of departmental resources, site-specific logistics,
experience, and personal preferences.CT scanebased simulation and dosimetry
TRUS-guided HDR catheter insertion is the first of four
steps using this method. The catheter insertion is performed
under anesthesia in an operating or procedure room. After
postoperative recovery, the patient is transferred to a CT
scanner for Step 2 where simulation images are obtained
and refinements of the catheter positions can be made.
CT is most often used for this purpose because they are
much more available and practical, although MRI scanners
provide better anatomic detail of the prostate and surround-
ing anatomy. Once approved, the CT image data set is
transferred to a treatment planning computer for Step 3
where contours of the target and OARs are generated.
Implant catheter distributions are registered and dose calcu-
lations are made to produce isodose clouds, dose volume
histograms, and virtual dosimetry images. After dosimetry
is reviewed and approved by the physician, the plan is up-
loaded to the treatment console, which transfers the source
delivery instructions to the robotic afterloader and where
data about the final step, HDR treatment, are monitored.
CT-based dosimetry offers excellent visualization of the
brachytherapy catheters and OARs (rectum, urethra, and
bladder) and it allows time for careful assessment of the
dosimetry (Fig. 1). Although the prostate is more accurately
contoured on TRUS, the CT scans can be fused with MRI
to gather even more detailed information on key anatomic
relationships. Except where dosimetry is performed in a
room shielded for HDR brachytherapy, CT simulation in
its current form often involves moving the patient. There-
fore, the potential disadvantages of CT dosimetry are the
need to move the patient and the time it takes to go from
one location to another to perform serial functions.
Moreover, changes in catheter positions that occur be-
tween simulation and treatment delivery must be identified
and corrected.TRUS-based dosimetry
This method uses the ultrasound images and computer
planning in ‘‘real-time’’ to simultaneously guide brachy-
therapy catheter placement and to perform the dosimetry
calculations. It has the advantages that the ultrasound
clearly delineates; the prostate capsule and treatment can
be delivered immediately afterward without moving the pa-
tient, if the implant procedure is performed in a properly
shielded venue (i.e., a shielded operating room or brachy-
therapy suite). TRUS-based planning, however, presents
some technical challenges. The image distortions
(‘‘shadows’’) produced by the posterior (dorsal) catheters
Fig. 1. CT-based dosimetry. Transverse, sagittal, coronal, and three-dimensional views.
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during treatment planning, and the catheters themselves
can obscure the prostate contour especially near the apex.
Schmid et al. (29) compared needle reconstruction accu-
racy with ultrasound to CT using a phantom. The two main
problems were spurious echoes on TRUS and difficulty
with craniocaudal needle tip identification (up to 6 mm).
In addition, definition of contours of the rectum and to a
lesser extent the bladder may be less accurately rendered
with real time TRUS planning than with CT-based plan-
ning. Newer 3D ultrasound probes will likely reduce some
of these technical difficulties (Fig. 2).Patient motion and multifractioned HDR
Monitoring and adjustment of catheters is not unique to
CT dosimetry or TRUS, but rather it is a key element of
multifraction HDR brachytherapy. Most of the catheter
displacement studies are based on the CT dosimetry pro-
cess, which involves moving the patient between simulation
and treatment delivery. Kovalchuk et al. (30) at the Mayo
Clinic did a dosimetry study of catheter displacement by
comparing initial dosimetry with doses that would be deliv-
ered with displaced catheters. They noted a mean needle
displacement of 3.5 mm between fractions. The
D90 $ 95% was 100% vs. 82% (initial vs. displaced),
V100 $ 95% was 87% vs. 53%, and urethra V115 # 10%
was 78% vs. 69%. Replanning improved the dosimetry.Huang et al. (31) at Henry Ford Hospital performed CT
scans before every HDR fraction in 13 patients and made
catheter adjustments when there was O3 mm catheter
displacement. Adjustments were made on 30% catheters
by an average of 5.8 mm. Without adjustments, the D90
would have been 10e32% less than the originally planned
and after making adjustments, the D90 was within 10% of
the original plan. Holly et al. (32) from Ontario Canada
performed cone-beam CT to assess catheter displacement
between planning and the first treatment in 20 consecutive
patients and evaluated the ability to improve dosimetry by
catheter readjustment. A mean catheter displacement of
11 mm was noted, and it would have resulted in a decrease
in mean V100 from 98% to 77% ( p ! 0.001), mean D90
from 111% to 73% ( p! 0.001), and an increase in urethra
D10 from 118% to 125% ( p 5 0.0094) had it not been cor-
rected. Catheter readjustments were helpful (V100 90%, D90
97%, and urethra D10 126%) but did not completely restore
the original dosimetry. These and other studies demonstrate
that catheter displacement can be a source of discrepancy
between the calculated and delivered dose (33e35). The
clinical significance of small (e.g., !3 mm) changes in
catheter position has not been demonstrated.
There are two TRUS treatment planning interfraction mo-
tion studies. Seppenwoolde et al. (36) in Holland studied
dosimetry of 3 patients to determine if a TRUS ultrasound
treatment plan (dwell positions and times) used for the first
HDR fraction could be used for subsequent fractions based
Fig. 2. Ultrasound-based dosimetry. Coronal, transverse, sagittal, and 3D views with 100% isodose lines and 3D cloud (red). 3D 5 three-dimensional. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
533D.J. Demanes, M.I. Ghilezan / Brachytherapy 13 (2014) 529e541on CT images. They found that the changes in ‘‘posture’’
(i.e., leg position) resulted in significant decreases in plan-
ning target volume (PTV) coverage (6e28%) and increases
in urethra dose. Martinez et al. (9) at WBH studied their first
23 patients treated with TRUS-based (four fraction, one
implant) HDR monotherapy. Serial TRUS prostate volume
measurements were made before each treatment and CT
was obtained before the first and after the last treatment.
They observed an increase in mean prostate volume from
pretreatment 31e37 cm3 by the first fraction. Therewas little
additional change by the end of treatment (38 cm3). The cor-
responding dosimetry between fractions was stable (D90
104e100% and D10 urethra 122e132%). The main differ-
ence was that the leg position was maintained stable at
WBH.
All these studies that address applicator and patient po-
sition during the course of HDR treatment highlight the
importance of applicator fixation, consistent positioning
(or not moving the patient at all), and the need to check
and, if necessary, adjust catheters before treatment. The
method of catheter and template fixation is another impor-
tant variable, which has not been addressed in these studies.
Regardless of the technical differences, there is no
outcome evidence that one treatment planning method
(TRUS vs. CT) is more or less effective than the other. In
an effort to improve patient comfort and work flow, the cur-
rent trend is toward delivering fewer treatments with larger
fractions. For example, one treatment per implant in 1e3
separate procedures eliminates interfraction displacement
or need for replanning, reduces patient immobilization time,
and eliminates an overnight hospital stay. In this regard,
portable CT scanners have recently been developed that
can be used to obtain the image data set necessary forHDR brachytherapy dosimetry. In terms of patient stability
andmotion avoidance, the portable CT process and workflow
will be very similar to TRUS treatment planning. The real
time dosimetry during needle placement will remain a
distinct advantage of the TRUS approach and the image qual-
ity an advantage of the CT. It is interesting to speculate that
technology development might lead to MRI-guided appli-
cator insertion and dosimetry with the dual advantages of real
time planning and high image quality.Target definition and normal tissue dosimetry
Standardization of prostate target is complicated by dif-
ferences in imaging techniques and variances in image
interpretation. There is no consensus whether to contour
the prostate at the capsule or with a margin. Although we
include the proximal seminal vesicles in the target, it is
not clear from the literature whether it is standard practice
to do so or not. OAR contouring is similarly subject to vari-
ability; particularly because the distinction between the rec-
toprostate (Denonvillier’s) fascia, and the bladder wall from
the prostate can be difficult.
HDR prostate monotherapy dose and fractionation
schedules have in common a high biological effective dose
(BED; 237e354 Gy range at alpha/beta ratio 1.5) and a
1.8e2.0 Gy equivalent dose of ~100e120 Gy. As a general
rule, the prostate target volume with or without the seminal
vesicles should be covered by at least 95% of the prescrip-
tion dose (i.e., V100 prostateO95%). Maintenance of dose
constraints to OARs is equally important. The urethra
maximum dose should be below 110% (ideally V100 urethra
!90%). We recommend further reduction to 105% for pa-
tients who have had a TURP; and it is advisable to wait for
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tate brachytherapy. The rectal dose constraints should be
75e80% (e.g., V75 rectum !1%). Bladder dosimetry
should be considered in terms of minimum and maximum
so the dose to bladder wall (surrogate for the peripheral
base of the prostate) does not receive!80% nor the bladder
neck and trigoneO80% (V80 bladder neck!1%). Updated
European and American guidelines for HDR prostate
brachytherapy that include normal tissue dose constraints
have been recently published (37, 38).Clinical experience with HDR monotherapy
A summary of the clinical experience with HDR mono-
therapy can be found in Table 1 (the treatment protocols),
Table 2 (late toxicity), and Table 3 (clinical outcomes).
In May 1995, the first trial of prostate cancer HDR
brachytherapy as monotherapy was opened at the Univer-
sity of Osaka, Japan and reported by Yoshioka et al. in
2000 (11). The original treatment regimen was 48 Gy in
eight fractions and five consecutive days delivered with a
single implant. In November 1996, the radiation dose was
increased to 54 Gy in nine fractions over 5 days. The treat-
ments were delivered twice daily with an interfraction time
of 6 h. Interestingly, 19/22 patients had high-risk features,
either T3e4 disease or prostate-specific antigen (PSA)
O20 ng/mL, and they received hormonal therapy.
They reported their results in 112 patients (68 high-risk)
in 2011 (39). Intermediate-risk patients and those patients
with prostate volumesO40 cm3 received 6e12 months of
neoadjuvant ADT, and high-risk patients were treated adju-
vant ADT for 3 years to life. The 5-year PSA diseaseefree
survival was 83% (low 85%, intermediate 93%, and high
79%), local control 97%, diseaseefree survival 87%, and
overall survival 96%. Initial PSA and younger age wereTable 1
High-dose-rate monotherapy published dose, fractionation, and dosimetry
Author (reference) Year N Risk group Dose  fractions T
Barkati et al. (50) 2012 79 Loweinterm. 10e11.5 Gy  3 3
Demanes et al. (42) 2011 157 Loweinterm. 7 Gy  6 4
Ghadjar et al. (48) 2009 36 Loweinterm. 9.5 Gy  4 3
Ghilezan et al. (52) 2012 50 Loweinterm. 12 Gy  2 2
44 13.5 Gy  2 2
Hoskins et al. (49) 2012 55 Interm.ehigh 8.5e9 Gy  4 3
109 10.5 Gy  3 3
33 13 Gy  2 2
Komiya et al. (41) 2013 51 Lowehigh 6.5 Gy  7 4
Mark et al. (46) 2010 317 Lowehigh 7.5 Gy  6 4
Martinez et al. (45) 2010 141 Loweinterm. 9.5 Gy  4 3
Prada et al. (53) 2012 40 Loweinterm. 19 Gy  1 1
Rogers et al. (47) 2012 284 Interm. 6.5 Gy  6 3
Yoshioka et al. (39) 2011 111 Interm.ehigh 6 Gy  9 5
6.5 Gy  7 4
Zamboglou et al. (51) 2013 141 Lowehigh 9.5 Gy  4 3
351 9.5 Gy  4 3
225 11.5 Gy  3 3
Interm. 5 intermediate; n/a 5 not applicable; TRUS 5 transrectal ultrasounthe only significant prognostic variables. Most toxicity
was genitourinary (GU). Acute Grade 3 ‘‘Common Toxicity
Criteria for Adverse Events’’ (CTCAE) toxicity was
observed in 6 patients. There were thirteen Grade 2 and
three Grade 3 toxicities reported.
A detailed dosimetry analysis of late toxicity in 83 pa-
tients treated with 54 Gy in nine fractions (median followup
3 years) was reported in 2009 (40). Toxicity correlations
with dose volume histogram parameters revealed greatest
difference for rectal toxicity were the V40 (volume of
rectum that receives 40% of the prescription dose) and
the D5 (the dose to 5 cm
3 of the rectum). Rectal toxicity
(V40 $ 8 cm
3 vs. V40! 8 cm
3) was 42% vs. 8%, respec-
tively; p! 0.001 and (D5cc $ 27 Gy vs. D5cc! 27 Gy)
was 50% vs. 11%, respectively; p! 0.001. Dosimetry pa-
rameters of the urethra of 15 patients with late urinary
toxicity were not significantly different from the 68 patients
without toxicity. This higher dose regimen was changed to
45.5 Gy in seven fractions over 4 days and it is now the one
widely used in Japan.
Komyia et al. (41) evaluated the quality of life 51 pa-
tients in various risk groups who were treated with a single
implant of 45.5 Gy in seven fractions. Long term adjuvant
ADTwas used for high-risk cases. Quality of life outcomes
were measured with the IPSS, the Functional Assessment
of Cancer Therapy-ProstatedFACT-P, and the Interna-
tional Index of Erectile Function questionnaire. The
FACT-P scores decreased for several months after HDR
but subsequently recovered to baseline. In the physical
and well-being domain, the score recovered baseline status
by 12 weeks. In the social/family well-being domain, base-
line status was achieved by 1 year. The total and compo-
nents of IPSS increased and sexual function decreased at
2 weeks after treatment, but returned to baseline after
12 weeks. There were few severe complications.otal dose (Gy) Implant number Implant interval (wk) Dosimetry
0e34.5 1 n/a CT
2 2 1 X-ray/CT
8 1 n/a CT
4 1 n/a TRUS
7 1
4e36 1 n/a CT
1.5 1
6 1
5.5 1 n/a
5 2 4 CT
8 1 n/a TRUS
9 1 n/a TRUS
9 2 1e5 CT
4 1 n/a X-ray/CT
5.5 1
8 1 n/a CT
8 2 2 TRUS
8 3 3 TRUS
d.
Table 2
Late toxicity
Author (reference) Year N Risk groups GU Grade 2 (%) GU Grade 3 (%) GI Grade 2 (%) GI Grade 3 (%) ED (%)
Barkati et al. (50) 2012 79 Loweinterm. 2e6 2e4 0e3 0 43
Demanes et al. (42) 2011 157 Loweinterm. 10 3 1 0 n/a
Ghadjar et al. (48) 2009 36 Loweinterm. 25 11 6 0 25
Ghilezan et al. (52) 2012 50
44
Loweinterm. 16 1 1 1 n/a
Hoskins et al. (49) 2012 55 Interm.ehigh 33e40* 3e16,*
3e6 strictures
4e13* 0e1* n/a
109
33
Komiya et al. (41) 2013 51 Lowehigh QoL (IPSS, FACT-P & IIEF) at baseline after 12 wk
Mark et al. (46) 2010 317 Lowehigh 3.2 0 1.3 1%
0.6% (Grade 4)
n/a
Martinez et al. (45) 2010 141 Loweinterm. Grade 1e3, 15e43 0 6.5 0 20
Prada et al. (53) 2012 40 Loweinterm. 0 0 0 0 NR
Rogers et al. (47) 2012 284 Interm. 1.5 0.6 0 0 17.4
Yoshioka et al. (39) 2011 112 Lowehigh 7 1 6 2 NR
Zamboglou
et al. (51)
2013 141 Lowehigh 15.6 9.2 0 0.7 11.1
351 16.5 4.8 1.7 0
225 17.6 3.8 3.5 0
GU 5 genitourinary; GI 5 gastrointestinal; ED 5 erectile dysfunction; interm. 5 intermediate; n/a 5 not applicable; RTOG 5 Radiation Therapy
Oncology Group; QoL 5 quality of life; IPSS 5 International Prostate Symptom score; FACT-P 5 Functional Assessment of Cancer Therapy-Prostate;
IIEF 5 International Index of Erectile Function; NR 5 not reported.
* RTOG toxicity scale.
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ing low- and intermediate-risk group patients with HDR
monotherapy in 1996 with 7 Gy  6 fractions in two im-
plants, 1 week apart. In 1997, Martinez et al. (9) at WBH
initiated an even more hypofractionated program of
9.5 Gy 4 fractions in one implant over 2 days using a TRUS
real time planning system. Given the similarity of the selec-
tion criteria, dosimetry, and radiobiology used at CET and
WBH, the two centers reported their results in 298 (CET
157 and WBH 141) patients together in 2011 (42). Eligibility
criteria were T1ceT2a, Gleason#7 (3þ 4, no perineural in-
vasion), and pretreatment PSA!15 ng/mL. Most of the pa-
tients had low- or intermediate-risk prostate cancer. The
median followup was 5.2 years during which a mean of 10
PSA tests were performed. Twenty-four percent of patientsTable 3
High-dose-rate monotherapy disease control
First author Year N Dose  fractions
Years
median fu
Local
control (%)
P
l
Barkati 2012 79 10e11.5 Gy  3 3.3 99
Demanes 2010 157 7 Gy  6 5.2 99
Ghadjar 2009 36 9.5 Gy  4 3 n/a 1
Hoskins 2012 55 8.5e9 Gy  4
10.5 Gy  3
4.5 n/a n
109 3
Komiya 2013 51 6.5 Gy  7 1.5 n/a
Mark 2010 317 7.5 Gy  6 8 n/a
Martinez 2010 141 9.5 Gy  4 5.2 99
Prada 2012 40 19 Gy  1 1.6 100 1
Rogers 2012 284 6 Gy  6 3 100 n
Yoshioka 2011 111 6 Gy  9 5.4 97
Zamboglou 2013 492 9.5 Gy  4
11.5 Gy  3
4.4 n/a
225
fu 5 followup; PSA 5 prostate-specific antigen; PSA-PFS 5 PSA p
interm. 5 intermediate; n/a 5 not applicable; DMFS 5 distant metastases-freereceived a median of 4 months ADT for downsizing the gland
volume or other reasons by referring physicians. The dosim-
etry parameters are shown in Table 4. The 5-year (n 5 158)
and 8-year (n 5 39) results were 99% local control, 97%
biochemical diseaseefree survival at 5 years (nadir þ2),
99% distant metastasisefree survival, 99% cause-specific
survival, and 95% overall survival. GU toxicity was 10%
transient Grade 2 urinary frequency or urgency and 3%Grade
3 urinary retention. Gastrointestinal (GI) toxicity was!1%.
The low morbidity rates were not demonstrably different be-
tween protocols. There was no demonstrable impact from the
short course of ADT.
During these early years of HDR monotherapy, there
were concerns about normal tissues toxicities and long-
term complications that might be associated with largeSA-PFS
ow (%)
PSA-PFS
interm. (%)
PSA-PFS
high (%) DMFS (%) CSS (%) OS (%)
88 n/a n/a n/a n/a
97 n/a 99 99 95
00 100 n/a n/a n/a n/a
/a 95 87 n/a n/a n/a
96 n/a n/a n/a
88 n/a n/a n/a
97 n/a 99 99 95
00 88 n/a 98 98 98
/a 94 n/a 99 100 98
85 93 79 n/a 87 96
95 93 93 n/a n/a 97.5
rogression-free survival, biochemical control (ASTRO or nadir þ2);
survival; CSS 5 cause-specific survival; OS 5 overall survival.
Table 4
High-dose-rate monotherapy prescription doses and normal tissue doses
Institution Dose (Gy  fx) BED (a/b 1.8) EBRT (1.8 Gy/fx) Bladder (%) Rectum (%) Urethra (%) D90 (%) V100 (%)
CET 7 Gy  6 205 Gy 103 Gy 80 80 110 O100 O97
WBH 9.5 Gy  4 239 Gy 119 Gy 80 75 120 O100 O96
fx 5 fraction; BED 5 biological effective dose; EBRT 5 external beam radiation therapy; CET 5 California Endocurietherapy Cancer Center;
WBH 5 William Beaumont Hospital.
Maximum normal tissue doses (as percent of prescription).
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with HDR monotherapy was the precision dosimetry and
ability of HDR to reliably partition the dose between the
prostate target and adjacent normal organs, and ultimately
in retrospect, the low alpha/beta ratio of prostate that makes
large fraction radiobiologically advantageous. Assuming a
prostate alpha/beta ratio of 1.5, these programs provided
BED in the range of 237e354 Gy, considerably higher than
the BED of 178 Gy achieved with EBRT to a total dose of
81 Gy in 1.8 Gy/fraction (43).
As a result of these favorable initial clinical experience
with HDR monotherapy, several radiation oncologists
around the world started HDR monotherapy programs of
their own (Tables 1e3). Most of the centers providing
HDR monotherapy follow, or started by following, pro-
grams similar to the Osaka, CET, or WBH.
HDR toxicity and comparisons with LDR (permanent
seed) brachytherapy
Grills et al. (44) in the United States were the first to
report the toxicity profile of HDR monotherapy. They
assessed comparably match HDR and permanent seed
implant, mostly low risk group, followed a median of
35 months (65 patients HDR 9.5 Gy  4 vs. 84 patients
Palladium103 120 Gy). ASTRO definition PSA control
diseaseefree survival was equally high for both treatments
(97% and 98%). The majority of toxicities were Grade 1.
Acute side effects were significantly lower with HDR
(dysuria 36% vs. 67%, frequency/urgency 54% vs. 92%,
and rectal pain 6% vs. 20%). Chronic frequency/urgency
was also less with HDR 32% vs. 56%. Urethral stricture
rates were not statistically different (8% vs. 3% p 5 0.17).
Potency preservation was better for HDR 83% vs. 55%.
WBH and CET did a comprehensive toxicity comparison
between 248 HDR monotherapy patients and 206 103Pd
permanent seeds patients (45). A short course (!6 months)
of neoadjuvant ADT was used in 30% of patients. The 5-
year actuarial biochemical control for monotherapy was
88% for HDR and 89% for seeds. There was no difference
in cancer mortality or overall survival.
Acute toxicity
HDR brachytherapy was associated with statistically
significant reductions in acute rates of dysuria (seeds 60%
vs. HDR 39%) and urgency/frequency (seeds 91% vs.
HDR 58%). HDR was also associated with lower rates ofrectal pain (seeds 17% vs. HDR 7%). Chronic toxicity:
HDR brachytherapy was associated with significantly less
Grade 1e2 chronic dysuria (seeds 22% vs. HDR 15%)
and urinary frequency and urgency (seeds 54% vs. HDR
43%). The occurrence of hematuria was slightly greater
for HDR than seeds (11% vs. 7%). The rate of urethral
stricture was equal (seeds 2.5% seeds vs. HDR 3%) with
the median time to diagnosis of 17 months. Chronic Grade
3 GU toxicity was low in both groups. Approximately 75%
of the HDR toxicities were self-limited and required little
or no intervention (Grade 1), 23% responded to therapy
(Grade 2), and about 2% had more prolong or more severe
(Grade 3) symptoms (mostly urinary frequency/urgency).
No HDR patient had Grade 4 toxicity. Erectile dysfunction
data were available for study in 58% of the cases. The 5-
year potency preservation rate was 80% for HDR of 80%
and 70% for seeds ( p 5 0.23).
Toxicity and outcome of other CET/Osaka-like regimens
(6e7 fractions, 1e2 implants)
Mark et al. (46) reported in abstract form the results of
301 patients with T1e2, Gleason 4e10, median PSA 9.3
(2.7e39.8) treated with HDR monotherapy. They adminis-
tered 7.5 Gy in six fractions in two implants performed
1 month apart. Urethral dose points (12e16) limited to
!105% of the prescription dose. Acute urinary retention
occurred in 5%. Late Radiation Therapy Oncology Group
(RTOG) urinary toxicity was 3% Grade 2 and Grade 3e4
(urethral stricture requiring dilation 6%). Late RTOG rectal
toxicity was Grade 1e2 (2.3%) and Grade 3e4 (0.3%). The
PSA progressionefree survival was 88% at 8 years.
Rogers et al. (47) reported their experience on 284 pa-
tients with intermediate-risk group patients treated with
two HDR implants to deliver six fractions of 6.5 Gy. The
5-year actuarial biochemical survival was 94.4%, local con-
trol and cause-specific survival 100%, and distant metasta-
sisefree survival 99%. Percent of core positive over 75%
and Stage T2c predicted for worse biochemical control.
Patients without these adverse risk factors had a 5-year
biochemical control of 97.5%. The incidence of side effects
was low. Unlike other reports, there were no urethral stric-
tures. Transient Grade 1 incontinence was found in 7.7% of
cases after treatment, but exclusive of patients with prior
transurethral resection or neurologic illness it was 2.5%.
Grade 1 RTOG rectal toxicity occurred in 4.2%. Potency
was maintained in 83% of patients 2 years after therapy.
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fractions, single implant)
Ghadjar et al. (48) reported on 36 patients with low- (28)
and intermediate- (8) risk prostate cancer treated with HDR
monotherapy in a single implant and four fractions of
9.5 Gy over 2 days. Acute Grade 3 GU toxicity rate was
3% and late GU toxicity 11%. There was no Grade 3 GI
toxicity. The 3-year PSA progressionefree survival rate
was 100%. The sexual preservation rate in patients without
ADT was 75%. Late Grade 3 GU toxicity was associated
with higher PTV doses as represented by the V100 (percent
target coverage by 100% isodose) and D90 (dose to 90% of
the PTV), and the urethral V120 (volume urethra receiving
$120% of the prescription dose).
Hoskin et al. (49), in the United Kingdom, conducted a
dose escalation trial for mostly intermediate- (52%) and
high-risk (44%) patients. A total of 197 patients were
treated with 34 Gy in four fractions, 36 Gy in four fractions,
31.5 Gy in three fractions, or 26 Gy in two fractions. Me-
dian followup times were 60, 54, 36, and 6 months. Inci-
dence of early Grade $3 GU morbidity was 3e7%, and
Grade 4 0e4%. Grade 3 or 4 early GI morbidity was not
observed. Late GU toxicity (3 year actuarial) Grade 3
was 3e16%. The 4-year stricture (requiring surgery) rate
was 3e7%. Late GI toxicity Grade 3 was 1%. There was
no late Grade 4 GI or GU toxicity. At 3 years, 99% of pa-
tients with intermediate-risk and 91% with high-risk dis-
ease were free of biochemical relapse ( p 5 0.02).
Researchers at Peter McCallum Cancer Center in
Australia reported the results of a Phase II prospective dose
escalation study of 79 low- and intermediate-risk prostate
cancer patients (50). Half of the patients had T2 and half
had Gleason 7 prostate cancer. They administered HDR
in a single implant over 2 days in three fractions; four
different dose schedules were evaluated (10, 10.5, 11, or
11.5 Gy). The 3- and 5-year biochemical control rates
(nadir þ 2) were 88% and 85%. There were no differences
in toxicity between doses. Acute rectal toxicity was nearly
all Grade 1 and acute Grade 3 urinary toxicity occurred in
only 1 patient. Chronic Grade 3 urinary toxicity was!10%
and no Grade 4 toxicities were recorded.
The group from Offenbach Germany, lead by Zambo-
glou and Baltas, obtained excellent results in 718 patients
using intraoperative TRUS treatment planning. The dose
and fractionation schedule evolved over time (51). Protocol
A (9.5 Gy  4 in one implant), protocol B (9.5 Gy  4
in two implants), and finally the current protocol C
(11.5 Gy  3 in three implants). The authors progressively
included higher risk group cases so that for protocol C 57%
of cases were intermediate- or high-risk compared with
27% in protocol A and 44% in protocol B. The median fol-
lowup by protocol was 7.7 years for 141 patients (protocol
A), 4.9 years for 351 patients (protocol B), and 2.1 years for
226 patients (protocol C). The 3-year biochemical control
for all patients was 95% and distant metastasisefreesurvival was 98%. The 5-year results were available for
protocols A and B (9.5 Gy  4). Biochemical control
was 97% and 94%. There were no significant differences
correlated with T score, PSA, Gleason score, or risk group.
Late Grade 3 GU and GI toxicities were 3.5% and 1.6%.
Urinary strictures that required urethrotomy (Grade 3 GU
toxicity) occurred in 1.8% and 2 patients required urinary
diversion to manage urinary incontinence (Grade 4 GU
toxicity). Although the followup is significantly less in pro-
tocol C, there were no apparent differences in tumor control
or morbidity between the three protocols.
Toxicity and outcome of ultra-hypofractionation (1e2
fractions)
Ghilezan et al. (52) reported on an ultra-
hypofractionated HDR monotherapy trial for low- and
intermediate-risk prostate cancer that accrued 100 patients.
The total dose was 24 Gy for the first 50 patients (one
implant, two fractions, and 6 h interfraction interval) and
27 Gy in the next 50 patients. The median followup was
17 months. There were no differences in acute or chronic
toxicities between the two doses. The maximum chronic
GU and GI toxicities Grade 2 or higher were #5% with
the exception of urinary frequency/urgency, which was
16%. These symptoms resolved by 6 months in most cases
(0% for the 24 Gy and 4.8% for the 27 Gy). The program
was changed to two implants 2e3 weeks apart to increase
the time for normal tissue repair and to shorten the time of
the procedure per day by removing the same day waiting
between fractions. It also eliminated the need for epidural
anesthesia and also improved patient tolerance and satisfac-
tion. Encouraged by this favorable tolerance and toxicity
profile, a new protocol of 19 Gy in one fraction was imple-
mented. There has been no Grade 3 or 4 GI or GU toxicity
with this protocol, during the first 3 months followup. Pa-
tients ineligible for single fraction HDR received the two
fraction protocol. Patients with T1c disease, PSA!10 ng/
mL, Gleason score 6, up to 3/12 cores positive, none
O50% tumor involvement, and patients’ age of 65 years
or older, are offered 12 Gy  2 fractions. All other cases
are treated with 13.5 Gy  2 fractions.
Prada et al. (53) from Spain published preliminary out-
comes in 29 low-risk and 11 intermediate-risk group pa-
tients treated with one fraction of 19 Gy. Hyaluronic acid
was injected in the rectoprostatic fascia to displace the
rectum posterior and away from the prostate. Although
the incidence of rectal complications with HDR monother-
apy is low with fractionated HDR brachytherapy, the au-
thors were concerned about the effect on the rectum of
giving treatment as a single large HDR dose. The hyaluron-
ic acid is injected after catheter placement so it does not
interfere with TRUS imaging and then is slowly absorbed
by the body over many weeks to months. The median
followup was 19 (8e32) months. Thirty-five percent of
patients received ADT before brachytherapy. Actuarial
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and 88% in intermediate-risk group patients. The CTCAE
Version 4 was used, which, parenthetically, is a system that
grades outlet obstruction requiring a catheter as Grade 1.
The procedures were well tolerated (one case of postoper-
ative urinary outlet obstruction) and the all the reported
acute and chronic toxicity was # Grade 1.
Hoskin et al. (54) compared acute GU and GI morbidity
in patients with intermediate- and high-risk prostate cancer.
They compared 13 Gy  2 (n 5 115), 19 Gy  1 (n 5 24),
and 20 Gy  1 (n 5 20) using the RTOG scoring system
and IPSS at 2, 4, and 12 weeks. The early (2 week) effect
on IPSS was greater for 20 Gy 1 fraction, but by 12 weeks
‘‘all groups were at pretreatment levels or less’’. Grade 3
GU toxicity was noted in 9% at 20 Gy  1, 2% for
13 Gy  2 fractions, and 0% for 19 Gy  1 fraction. The
numbers of patients were too small to demonstrate statisti-
cal significance. There were no Grade 4 complications. The
single fraction programs were associated with a significant
increase in the need for urinary catheters (19 Gy 21% and
20 Gy 29% compared with 13 Gy  2 7%). The authors
suggest that tolerance to single fraction HDR monotherapy
may have been reached at 20 Gy  1.
A randomized Phase II trial sponsored by Sunnybrook
Health Science Center in Toronto (principal investigator
Dr. Gerard Morton) was opened in 2013 in Canada
(ClinicalTrials.gov identifier NCT01890096). Low- and
intermediate-risk prostate cancer patients with a gland size
up to 60 cm3 are randomized to either two fractions of
13.5 Gy delivered in two separate implants 7e13 days apart
or a single implant with one fraction of 19 Gy. CT and
TRUS-based dosimetry are allowed. The primary end point
is patient-reported toxicity and health-related quality of life
at 1 year.Focal prostate brachytherapy and organ at risk dose
de-escalation
At the University of California Los Angeles research
efforts have been directed toward focal prostate brachyther-
apy using HDR. Kamrava et al. (55) published a dosimetric
analysis assessing the impact on target coverage and dose
to OARs with hemi-gland compared with whole-gland
treatment. As expected, the dose to OARs was significantly
lower with hemi-gland treatments. Focal HDR treatment
planning using interactive multimodality image combina-
tion such as multiparametric MRI and spectroscopy along
with sophisticated image registration alogorithms are
currently being investigated (56).HDR monotherapy as salvage treatment
HDR monotherapy has been used for treatment of recur-
rent prostate cancer. Lee et al. (25) at the University of Cal-
ifornia San Francisco reviewed 21 cases they treated with
6 Gy  6 fractions HDR monotherapy using TRUS-guided and CT treatmenteplanned HDR brachytherapy.
Approximately half of the cases received neoadjuvant
ADT. The median followup was 19 (6e84) months.
CTCAE Version 3 Grade 1 or 2 GU morbidity was reported
in 18 patients by 3 months after HDR salvage. Three pa-
tients developed Grade 3 GU toxicity. Three patients had
transient (!3 months) Grade 1 or 2 GI toxicity. The 2-
year biochemical control was 89%. Failure to achieve a
PSA nadir of #1.0 ng/mL was associated with biochemical
recurrence and the development of distant metastasis.
Tharp et al. (26) reported the 5-year results on 7 patients
treated with HDR salvage after either external beam radia-
tion (n 5 5) or permanent seed implant (n 5 2). Median
followup was 58 (27e63) months. The disease-free survival
was 71% (median not reached). Two patients died of met-
astatic disease but there were no local failures. One patient
developed Grade 2 rectal bleeding attributed to radiation
therapy. Although disease control was good and GI toxicity
was low, the GU morbidity rate was high. Five patients
(71%) developed symptomatic urethral strictures; 2 of these
patients had prior TURP and 2 of them (prior seed brachy-
therapy) required artificial sphincters.
Yamada et al. (57) reported the results of a Phase II
study of 40 patients treated with HDR brachytherapy
(8 Gy  4 in one implant) after prior EBRT (range
68.4e86.4 Gy). The median pretreatment PSA was
3.45 ng/mL. Twelve patients had neoadjuvant ADT. The
median followup was 38 months and time from EBRT to
recurrence was 73 months. PSA (nadir þ 2) 5 year
disease-free survival was 70% and cause-specific survival
was 94%. Three patients developed distant metastasis. IPSS
returned to baseline in 65% cases by 4.5 months. Patients
with higher levels of GU symptoms at baseline were more
likely to have Grade 2 urinary morbidity (but not so for
Grade 3). Approximately 20% of cases had Grade 2 GI
morbidity.Discussion
HDR monotherapy is the logical extension of HDR used
with EBRT as dose escalation and it builds on the large
worldwide experience of permanent seed implants without
EBRT. There is good evidence in the literature that HDR
monotherapy is a safe and effective treatment for prostate
cancer. The large doses per fraction take advantage of the
radiobiology (low alpha/beta ratio) to potentially render
HDR the most efficient and convenient form of radiation
therapy. Although patients with early- and intermediate-
risk groups are optimal candidates, patients with high-risk
group disease also have reported excellent outcomes with
HDR monotherapy when compared with other treatment
methods. HDR delivers a therapeutic margin of safety for
patients with periprostatic or seminal vesicle extension.
Prostate HDR brachytherapy is versatile; it can be used
as monotherapy, monotherapy salvage, combined with
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to reduce disease burden to improve remission rates.
HDR dosimetry is prospective (done before source de-
livery), consistent, and reliable because it is not impacted
by setup errors, interfraction and intrafraction organ mo-
tion, prostate swelling, or shrinkage during treatment deliv-
ery. Furthermore, target coverage is verifiable through
pretreatment image guidance designed to avoid unrecog-
nized ‘‘dwell position displacement’’. Dose modulation of
the stepping source can compensate for catheter spacing
and volume discrepancies by using ‘‘optimization’’ pro-
grams so that dose painting and dose sculpting can be done
for dose adjustments within the target boundaries. Such ca-
pacities make HDR an excellent choice for monotherapy or
for EBRT boost; and in properly selected cases, it can be
used to reduce or eliminate radiation to parts of the prostate
(focal therapy or dose de-escalation). These measures may
enhance the therapeutic index by delivery of dose in pro-
portion to the extent and severity of the disease, and it
can reduce morbidity by limiting dose to normal structures.
The excellent results of HDR prostate brachytherapy
coupled with the radiobiological advantage of higher doses
per fraction especially in tumors with low alpha/beta have
prompted clinical trials of stereotactic body radiation ther-
apy (SBRT) to deliver the full course of external beam ther-
apy in 4e6 fractions like HDR (58e65). Fuller et al. (66)
performed an analysis to determine if SBRT could repro-
duce the dosimetry achieved with HDR brachytherapy in
what was termed ‘‘virtual HDR’’. The real stereotactic
plans were compared with ‘‘simulated’’ HDR plans in
which the theoretical brachytherapy trajectories were in-
serted on the same contours used for SBRT planning.
Although the V125 and V150 were significantly higher with
HDR, the urethral doses were lower with the SBRT plans
suggesting to the authors that SBRT may limit urethra
doses more effectively than HDR. Although such plan com-
parisons are valuable, they are highly dependent on the
treatment planning process. In a more recent dosimetric
analysis comparing virtual SBRT with actual HDR mono-
therapy plans from treated patients have demonstrated
HDR achieves significantly higher intraprostatic doses
while achieving similar urethral dose and lower maximum
rectal dose compared with virtual SBRT treatment planning
(67). There are no direct clinical comparison outcome
studies of HDR, permanent seeds, or SBRT.
Because ADT has not been shown to enhance disease
control with HDR prostate brachytherapy and ADT is usu-
ally not required for downsizing of prostate volume with
HDR brachytherapy, it can usually be omitted for favorable
risk group cases.Conclusions
Most centers in the United States have used HDR mono-
therapy to treat low- and intermediate-risk group disease
whereas those in Asia and Europe treat patients in all riskgroups. HDR brachytherapy can be used to deliver the dose
to a definable margin around the prostate and into the
seminal vesicles; thus it effectively treats patients with
local extension beyond the prostate. Whether higher risk
group patients should have HDR monotherapy or HDR
combined therapy with EBRT remains to be determined.
There is no consensus on the optimal dose and fractionation
schedule for HDR brachytherapy. The longest followup
for outcomes is with moderate-hypofractionation (4e9
fractions), but excellent results are being reported with
ultra-hypofractionation (1e3 fractions). The emergence of
ultra-hypofractionation with only 1e2 treatments makes
HDR logistically comparable to seed implant and adds a
high degree of dosimetry control and accuracy in brachy-
therapy. There are two simulation and dosimetry methods
(TRUS and CT). The advantages of TRUS are its use of
real-time imaging and interactive dosimetry whereas CT
dosimetry provides the clearest images of catheters and
the relationship of the implant to adjacent organs. The
TRUS approach is most time efficient. Regardless of the
imaging modality and treatment planning system, HDR
monotherapy is an excellent treatment modality for the
management of prostate cancer.References
[1] Stromberg J, Martinez A, Gonzalez J, et al. Ultrasound-guided high
dose rate conformal brachytherapy boost in prostate cancer: Treat-
ment description and preliminary results of a phase I/II clinical trial.
Int J Radiat Oncol Biol Phys 1995;33:161e171.
[2] Kovacs G, Galalae R, Wirth B, et al. Improvement of interstitial
brachytherapy for localized prostate neoplasms with a new implan-
tation technique. Strahlenther Onkol 1995;171:685e688.
[3] Martinez A, Gonzalez J, Stromberg J, et al. Conformal prostate
brachytherapy: Initial experience of a phase I/II dose-escalating
trial. Int J Radiat Oncol Biol Phys 1995;33:1019e1027.
[4] Mate TP, Gottesman JE, Hatton J, et al. High dose-rate afterloading
192Iridium prostate brachytherapy: Feasibility report. Int J Radiat
Oncol Biol Phys 1998;41:525e533.
[5] Kovacs G, Galalae R, Loch T, et al. Prostate preservation by com-
bined external beam and HDR brachytherapy in nodal negative
prostate cancer. Strahlenther Onkol 1999;175(Suppl. 2):87e88.
[6] Demanes DJ, Rodriguez RR, Altieri GA. High dose rate prostate
brachytherapy: The California Endocurietherapy (CET) method.
Radiother Oncol 2000;57:289e296.
[7] Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using
conformal high-dose-rate brachytherapy improves outcome in unfa-
vorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:
316e327.
[8] Martinez AA, Kestin LL, Stromberg JS, et al. Interim report of
image-guided conformal high-dose-rate brachytherapy for patients
with unfavorable prostate cancer: The William Beaumont phase II
dose-escalating trial. Int J Radiat Oncol Biol Phys 2000;47:
343e352.
[9] Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective
study of the use of conformal high-dose-rate brachytherapy as
monotherapy for the treatment of favorable stage prostate cancer:
A feasibility report. Int J Radiat Oncol Biol Phys 2001;49:61e69.
[10] Rodriguez RR, Demanes DJ, Altieri GA. High dose rate brachyther-
apy in the treatment of prostate cancer. Hematol Oncol Clin North
Am 1999;13:503e523.
540 D.J. Demanes, M.I. Ghilezan / Brachytherapy 13 (2014) 529e541[11] Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial
brachytherapy as a monotherapy for localized prostate cancer:
Treatment description and preliminary results of a phase I/II clinical
trial. Int J Radiat Oncol Biol Phys 2000;48:675e681.
[12] Edmundson GK, Rizzo NR, Teahan M, et al. Concurrent treatment
planning for outpatient high dose rate prostate template implants. Int
J Radiat Oncol Biol Phys 1993;27:1215e1223.
[13] Edmundson GK, Yan D, Martinez AA. Intraoperative optimization
of needle placement and dwell times for conformal prostate brachy-
therapy. Int J Radiat Oncol Biol Phys 1995;33:1257e1263.
[14] White EC, Kamrava MR, Demarco J, et al. High-dose-rate prostate
brachytherapy consistently results in high quality dosimetry. Int J
Radiat Oncol Biol Phys 2013;85:543e548.
[15] Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy
of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:
1095e1101.
[16] Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence
that prostate tumors show high sensitivity to fractionation (low
alpha/beta ratio), similar to late-responding normal tissue. Int J Ra-
diat Oncol Biol Phys 2002;52:6e13.
[17] Fowler JF. The radiobiology of prostate cancer including new as-
pects of fractionated radiotherapy. Acta Oncol 2005;44:265e276.
[18] Peddada AV, Jennings SB, Faricy PO, et al. Low morbidity
following high dose rate brachytherapy in the setting of prior tran-
surethral prostate resection. J Urol 2007;178:1963e1967.
[19] Monroe AT, Faricy PO, Jennings SB, et al. High-dose-rate brachy-
therapy for large prostate volumes (O or 550cc)dUncompromised
dosimetric coverage and acceptable toxicity. Brachytherapy 2008;7:
7e11.
[20] Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of
three-dimensional computer-optimized high-dose-rate prostate
brachytherapy in the management of localized prostate cancer.
Brachytherapy 2006;5:157e164.
[21] Hermesse J, Biver S, Jansen N, et al. Dosimetric comparison of
high-dose-rate brachytherapy and intensity-modulated radiation
therapy as a boost to the prostate. Int J Radiat Oncol Biol Phys
2010;76:269e276.
[22] Holly R, Myrehaug S, Kamran A, et al. High-dose-rate prostate
brachytherapy in a patient with bilateral hip prostheses planned us-
ing megavoltage computed tomography images acquired with a he-
lical tomotherapy unit. Brachytherapy 2009;8:70e73.
[23] Hsu IC, Pickett B, Shinohara K, et al. Normal tissue dosimetric
comparison between HDR prostate implant boost and conformal
external beam radiotherapy boost: Potential for dose escalation.
Int J Radiat Oncol Biol Phys 2000;46:851e858.
[24] Jo Y, Fujii T, Hara R, et al. Salvage high-dose-rate brachytherapy
for local prostate cancer recurrence after radiotherapydPreliminary
results. BJU Int 2012;109:835e839.
[25] Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate
brachytherapy salvage for local prostate cancer recurrence after
radiotherapy: The University of California-San Francisco experi-
ence. Int J Radiat Oncol Biol Phys 2007;67:1106e1112.
[26] Tharp M, Hardacre M, Bennett R, et al. Prostate high-dose-rate
brachytherapy as salvage treatment of local failure after previous
external or permanent seed irradiation for prostate cancer. Brachy-
therapy 2008;7:231e236.
[27] De Cicco L, Vavassori A, Cattani F, et al. Salvage high dose rate
brachytherapy after primary external beam irradiation in localized
prostate cancer: A case report. Tumori 2009;95:553e556.
[28] Niehoff P, Loch T, Nurnberg N, et al. Feasibility and preliminary
outcome of salvage combined HDR brachytherapy and external
beam radiotherapy (EBRT) for local recurrences after radical pros-
tatectomy. Brachytherapy 2005;4:141e145.
[29] Simnor T, Li S, Lowe G, et al. Justification for inter-fraction correc-
tion of catheter movement in fractionated high dose-rate brachyther-
apy treatment of prostate cancer. Radiother Oncol 2009;93:
253e258.[30] Schmid M, Crook JM, Batchelar D, et al. A phantom study to assess
accuracy of needle identification in real-time planning of
ultrasound-guided high-dose-rate prostate implants. Brachytherapy
2013;12:56e64.
[31] Kovalchuk N, Furutani KM, Macdonald OK, et al. Dosimetric effect
of interfractional needle displacement in prostate high-dose-rate
brachytherapy. Brachytherapy 2012;11:111e118.
[32] Huang Y, Miller B, Doemer A, et al. Online correction of catheter
movement using CT in high-dose-rate prostate brachytherapy.
Brachytherapy 2013;12:260e266.
[33] Holly R, Morton GC, Sankreacha R, et al. Use of cone-beam imag-
ing to correct for catheter displacement in high dose-rate prostate
brachytherapy. Brachytherapy 2011;10:299e305.
[34] Foster W, Cunha JA, Hsu IC, et al. Dosimetric impact of interfrac-
tion catheter movement in high-dose rate prostate brachytherapy. Int
J Radiat Oncol Biol Phys 2011;80:85e90.
[35] Kolkman-Deurloo IK, Roos MA, Aluwini S. HDR monotherapy for
prostate cancer: A simulation study to determine the effect of cath-
eter displacement on target coverage and normal tissue irradiation.
Radiother Oncol 2011;98:192e197.
[36] Seppenwoolde Y, Kolkman-Deurloo IK, Sipkema D, et al. HDR
prostate monotherapy: dosimetric effects of implant deformation
due to posture change between TRUS- and CT-imaging. Radiother
Oncol 2008;86:114e119.
[37] Hoskin PJ, Colombo A, Henry A, et al. GEC/ESTRO recommenda-
tions on high dose rate afterloading brachytherapy for localised
prostate cancer: An update. Radiother Oncol 2013;107:325e332.
[38] Yamada Y, Rogers L, Demanes DJ, et al. American Brachytherapy
Society consensus guidelines for high-dose-rate prostate brachyther-
apy. Brachytherapy 2012;11:20e32.
[39] Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic high-dose-
rate brachytherapy for prostate cancer: Five-year results of an
extreme hypofractionation regimen with 54 Gy in nine fractions.
Int J Radiat Oncol Biol Phys 2011;80:469e475.
[40] Konishi K, Yoshioka Y, Isohashi F, et al. Correlation between dosi-
metric parameters and late rectal and urinary toxicities in patients
treated with high-dose-rate brachytherapy used as monotherapy for
prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:1003e1007.
[41] Komiya A, Fujiuchi Y, Ito T, et al. Early quality of life outcomes in
patients with prostate cancer managed by high-dose-rate brachyther-
apy as monotherapy. Int J Urol 2013;20:185e192.
[42] Demanes DJ, Martinez AA, Ghilezan M, et al. High-dose-rate
monotherapy: Safe and effective brachytherapy for patients with
localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;81:
1286e1292.
[43] Bossi A. Quelle modalite pour la curietherapie du cancer de prostate
(Which modality for prostate brachytherapy?). Cancer Radiother
2010;14(6e7):488e492.
[44] Grills IS, Martinez AA, Hollander M, et al. High dose rate brachy-
therapy as prostate cancer monotherapy reduces toxicity compared
to low dose rate palladium seeds. J Urol 2004;171:1098e1104.
[45] Martinez AA, Demanes J, Vargas C, et al. High-dose-rate prostate
brachytherapy: An excellent accelerated-hypofractionated treatment
for favorable prostate cancer. Am J Clin Oncol 2010;33:481e488.
[46] Mark RJ, Anderson PJ, Akins RS, et al. Interstitial high-dose-rate
brachytherapy as monotherapy for early stage prostate cancer; me-
dian 8-year results in 301 patients. Brachytherapy 2010;9(Suppl.
23):102.
[47] Rogers CL, Alder SC, Rogers RL, et al. High dose brachytherapy as
monotherapy for intermediate risk prostate cancer. J Urol 2012;187:
109e116.
[48] Ghadjar P, Keller T, Rentsch CA, et al. Toxicity and early treatment
outcomes in low- and intermediate-risk prostate cancer managed by
high-dose-rate brachytherapy as a monotherapy. Brachytherapy
2009;8:45e51.
[49] Hoskin P, Rojas A, Lowe G, et al. High-dose-rate brachytherapy
alone for localized prostate cancer in patients at moderate or high
541D.J. Demanes, M.I. Ghilezan / Brachytherapy 13 (2014) 529e541risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012;
82:1376e1384.
[50] Barkati M, Williams SG, Foroudi F, et al. High-dose-rate brachy-
therapy as a monotherapy for favorable-risk prostate cancer: A
phase II trial. Int J Radiat Oncol Biol Phys 2012;82:1889e1896.
[51] Zamboglou N, Tselis N, Baltas D, et al. High-dose-rate interstitial
brachytherapy as monotherapy for clinically localized prostate can-
cer: Treatment evolution and mature results. Int J Radiat Oncol Biol
Phys 2013;85:672e678.
[52] Ghilezan M, Martinez A, Gustason G, et al. High-dose-rate brachy-
therapy as monotherapy delivered in two fractions within one day
for favorable/intermediate-risk prostate cancer: Preliminary toxicity
data. Int J Radiat Oncol Biol Phys 2012;83:927e932.
[53] Prada PJ, Jimenez I, Gonzalez-Suarez H, et al. High-dose-rate inter-
stitial brachytherapy as monotherapy in one fraction and transperi-
neal hyaluronic acid injection into the perirectal fat for the treatment
of favorable stage prostate cancer: Treatment description and pre-
liminary results. Brachytherapy 2012;11:105e110.
[54] Hoskin P, Rojas A, Ostler P, et al. High-dose-rate brachytherapy
alone given as two or one fraction to patients for locally advanced
prostate cancer: Acute toxicity. Radiother Oncol 2014;110:
268e271.
[55] Kamrava M, Chung MP, Kayode O, et al. Focal high-dose-rate
brachytherapy: A dosimetric comparison of hemigland vs. con-
ventional whole-gland treatment. Brachytherapy 2013;12:
434e441.
[56] Reed G, Cunha JA, Noworolski S, et al. Interactive, multi-modality
image registrations for combined MRI/MRSI-planned HDR prostate
brachytherapy. J Contemp Brachytherapy 2011;3:26e31.
[57] Yamada Y, Kollmeier MA, Pey X, et al. A phase II study of salvage
high-dose-rate brachytherapy for the treatment of locally recurrentprostate cancer after definitive external beam radiotherapy. Brachy-
therapy 2014;13:111e116.
[58] Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy
for organ-confined prostate cancer. BMC Urol 2010;10:1.
[59] Martin A, Gaya A. Stereotactic body radiotherapy: A review. Clin
Oncol (R Coll Radiol) 2010;22:157e172.
[60] Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation ther-
apy: A novel treatment modality. Nat Rev Clin Oncol 2010;7:
44e54.
[61] Friedland JL, Freeman DE, Masterson-McGary ME, et al. Stereo-
tactic body radiotherapy: An emerging treatment approach for local-
ized prostate cancer. Technol Cancer Res Treat 2009;8:387e392.
[62] Abdel-Wahab M, Pollack A. Radiotherapy: Encouraging early data
for SBRT in prostate cancer. Nat Rev Urol 2009;6:478e479.
[63] Hossain S, Xia P, Chuang C, et al. Simulated real time image guided
intrafraction tracking-delivery for hypofractionated prostate IMRT.
Med Phys 2008;35:4041e4048.
[64] King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy
for localized prostate cancer: Interim results of a prospective phase
II clinical trial. Int J Radiat Oncol Biol Phys 2009;73:1043e1048.
[65] Teh BS, Ishiyama H, Mathews T, et al. Stereotactic body radiation
therapy (SBRT) for genitourinary malignancies. Discov Med 2010;
52:255e262.
[66] Fuller DB, Naitoh J, Lee C, et al. Virtual HDR CyberKnife treat-
ment for localized prostatic carcinoma: Dosimetry comparison with
HDR brachytherapy and preliminary clinical observations. Int J Ra-
diat Oncol Biol Phys 2008;70:1588e1597.
[67] Spratt DE, Scala LM, Folkert M, et al. A comparative dosimetric
analysis of virtual stereotactic body radiotherapy to high-dose-rate
monotherapy for intermediate-risk prostate cancer. Brachytherapy
2013;12:428e433.
